Targeting Combined Therapy to Cancer Stem Cells (NANOSTEM)

Cancer stem cells (CSCs) are responsible for initiating cancer, and are therefore highly sought for therapeutic target. Unfortunately, CSCs are a minority among tumour cells, and highly resistant to conventional treatments. Breast cancer CSCs express CD44, a unique membrane receptor, and can thus be specifically targeted. NANOSTEM will develop drug delivery systems that will specifically target CD44-expressing CSCs, enter the cells and release a chemotherapeutic drug, thus selectively killing the tumorigenic cell. The project will use model animals to evaluate the therapeutic potential and toxicity of each system.

Project coordinator:
Simo Schwartz Jr (ES)
sschwartz@ir.vhebron.net

Project partners:
Patrick Boisseau (FR)
Rogerio Gaspar (PT)
Lorea Mendoza Arteche (ES-B)